However, reimbursement is only possible when: The injection is not bundled into another procedure Documentation clearly supports medical necessity Correct modifiers and codes are used Failure to meet these conditions often results in denials or downcoding
Similarly, in a letter to the committee, the Alliance for Pharmacy Compounding urged the FDA to address safety concerns through targeted safeguards rather than outright restrictions
No pathway to BPC-157 approval through expedited review programs (Fast Track, Breakthrough Therapy) is currently listed in the FDA's public database
Injury severity, age, metabolic health, protein intake, sleep quality, training load, inflammation, and rehabilitation strategy all matter
the typical reply turnaround is well under 24 hours